Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice

Archives of Medical Science

Volumn 10, Issue 1, 2014, Pages 154-160

  Pingel, Simon ^a   Tiyerili, Vedat ^a   Mueller, Jens ^a   Werner, Nikos ^a   Nickenig, Georg ^a   Mueller, Cornelius ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Atherosclerosis; Dabigatran; Endothelial function; Thrombin inhibition

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; DABIGATRAN; PLACEBO; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CHEMOLUMINESCENCE; DRUG BLOOD LEVEL; FOOD INTAKE; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; THROMBIN TIME; VASCULAR RING; VASODILATATION;

EID: 84900598078     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.40742     Document Type: Article

References (37)

1. Lusis F. Atherosclerosis. Nature 2000; 407: 233-41.
2. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost 2009; 7 Suppl. 1: 328-31.
3. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
4. Jawień J, Olszanecki R, Nowak B, Marcinkiewicz J. Apolipoprotein E knockout mice: an experimental model to study inflammatory mechanisms of atherosclerosis and to screen a putative anti-atherogenic properties of drugs. Centr Eur J Immunol 2012; 37: 36-44.
5. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci 2012; 8: 794-804.
6. Borissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 2009; 82: 392-403.
7. Kataoka H, Hamilton JR, McKemy DD, et al. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003; 102: 3224-31.
8. Mizuno O, Hirano K, Nishimura J, Kubo C, Kanaide H. Mechanism of endothelium-dependent relaxation induced by thrombin in the pig coronary artery. Eur J Pharmacol 1998; 351: 67-77.
9. Hamilton JR, Cocks TM. Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery. Br J Pharmacol 2000; 130: 181-8.
10. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36.
11. Warfarin Antiplatelet Vascular Evaluation Trial Investigators; Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-27.
12. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-74.
13. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.
14. Widder JD, Guzik TJ, Mueller CF, et al. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol 2007; 277: 62-8.
15. Wassmann S, Werner N, Czech T, Nickenig G. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res 2006; 99: e74-83.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
17. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
18. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012; 137: 572-4.
19. Harenberg J, Giese C, Marx S, Kramer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38: 16-22.
20. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug dabigatran etexilate. Thromb Haemost 2007; 98: 155-62.
21. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
22. Gudmundsdóttir IJ, Lang NN, Boon NA, et al. Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. J Am Coll Cardiol 2008; 51: 1749-56.
23. Rudolph V, Rudolph TK, Schopfer FJ, et al. Bivalirudin decreases NO bioavailibility by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther 2008; 327: 324-31.
24. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91; 7A-11A.
25. Gorlach A, Diebold I, Schini-Kerth VB, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 2001; 89: 47-54.
26. Wachowicz B, Olas B, Zbikowska HM, Buczyński A. Generation of reactive oxygen species in blood platelets. Platelets 2002; 13: 175-82.
27. Martorell L, Martínez-González J, Rodríguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 2008; 99: 305-15.
28. Mieczkowska J, Mosiewicz J, Barud W, Kwaśniewski W. Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome. Arch Med Sci 2011; 7: 634-41.
29. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994; 144: 975-85.
30. Maruyama I, Shigeta K, Miyahara H, et al. Thrombin activates NF-kappa B through thrombin receptor and results in proliferation of vascular smooth muscle cells: role of thrombin in atherosclerosis and restenosis. Ann N Y Acad Sci 1997; 811: 429-36.
31. May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-10.
32. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
33. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
34. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2787-92.
35. Seehaus S, Shahzad K, Kashif M, et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation 2009; 120: 774-84.
36. Mohler ER 3rd. Atherothrombosis: wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med 2007; 357: 293-6.
37. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115: 15-20.